Adriana Marton, Seyed Ehsan Saffari, Manfred Rauh, Ruo-Ning Sun, Armin M Nagel, Peter Linz, Tzy Tiing Lim, Kaoru Takase-Minegishi, Anastacia Pajarillaga, Sharon Saw, Norihiko Morisawa, Wan Keat Yam, Shintaro Minegishi, John J Totman, Serena Teo, Louis L Y Teo, Choon Ta Ng, Kento Kitada, Johannes Wild, Jean-Paul Kovalik, Friedrich C Luft, Peter J Greasley, Calvin W L Chin, David K L Sim, Jens Titze
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac outcomes due to their osmotic diuretic potential. OBJECTIVES: The goal of this study was to test the hypothesis that vasopressin-driven urine concentration overrides the osmotic diuretic effect of glucosuria induced by dapagliflozin treatment. METHODS: DAPA-Shuttle1 (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment) was a single-center, double-blind, randomized, placebo-controlled trial, in which patients with chronic heart failure NYHA functional classes I/II and reduced ejection fraction were randomly assigned to receive dapagliflozin 10 mg daily or placebo (1:1) for 4 weeks...
April 16, 2024: Journal of the American College of Cardiology